Advances in pediatric rheumatology

Future Rheumatology

Volumn 3, Issue 3, 2008, Pages 239-251

  Cimaz, Rolando ^a,b   Prieur, Anne Marie ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Autoinflammatory disorder; Classification; Juvenile idiopathic arthritis; Kawasaki disease; Pathogenesis; Treatment

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIINFLAMMATORY AGENT; ATLIZUMAB; ATORVASTATIN; AZATHIOPRINE; BILE ACID SEQUESTRANT; BISPHOSPHONIC ACID DERIVATIVE; COLCHICINE; CORTICOSTEROID; ETANERCEPT; FIBRIC ACID DERIVATIVE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; NICOTINIC ACID; PLACEBO; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; SIMVASTATIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; BEHCET DISEASE; CHILD; CINCA SYNDROME; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; HUMAN; IMMUNE SYSTEM; JUVENILE RHEUMATOID ARTHRITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; ONSET AGE; PEDIATRICS; PRIORITY JOURNAL; PROGNOSIS; RECURRENT FEVER; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 47249132852     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.3.3.239     Document Type: Article

References (57)

1. Cilliers AM: Rheumatic fever and its management. BMJ 333(7579), 1153-1156 (2006).
2. Neven B, Callebaut I, Prieur AM et al.: Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood 103(7), 2809-2815 (2004).
3. Ryan JG, Goldbach-Mansky R: The spectrum of autoinflammatory diseases: recent bench to bedside observations. Curr. Opin. Rheumatol. 20(1), 66-75 (2008).
4. Rosé CD, Wouters CH, Meiorin S et al.: Pediatric granulomatous arthritis: an international registry. Arthritis Rheum. 54(10), 3337-3344 (2006).
5. Tattoli I, Travassos LH, Carneiro LA, Girardin SE: The nodosome: Nod1 and Nod2 control bacterial infections and inflammation. Semin. Immunopathol. 29(3), 289-301 (2007).
6. Saito M, Nishikomori R, Kambe N et al.: Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. Blood 111, 2132-2141 (2008).
7. Holzelova E, Vornarbourg C, Stolzenberg MC et al.: Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N. Engl. J. Med. 351(14), 1409-1418 (2004).
8. Neven B, Valayannopoulos V, Quartier P et al.: Allogeneic bone marrow transplantation in mevalonic aciduria. N. Engl. J. Med.. 356(26), 2700-2703 (2007).
9. Prahalad S: Genetics of juvenile idiopathic arthritis: an update. Curr. Opin. Rheumatol. 16(5), 588-594 (2004).
10. de Kleer IM, Albani S, Prakken BJ: T-cell regulation in juvenile idiopathic arthritis. Future Rheumatol. 1(1), 111-119 (2006).
11. Lehman TJ: Juvenile idiopathic arthritis and HSP60 vaccination: selective down-regulation? Lancet 366(9479), 9-10 (2005).
12. Massa M, Passalia M, Magni-Manzoni S et al.: Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis Rheum. 56(5), 1648-1657 (2007).
13. Kamphuis S, Kuis W, de Jager W et al.: Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 366(9479), 50-56 (2005).
14. Lovell DJ, Giannini EH, Reiff A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342 (11), 763-769 (2000).
15. Ruperto N, Lovell DJ, Cuttica R et al.: A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 56(9), 3096-3106 (2007).
16. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN: Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin. Rheumatol. 27(1), 67-76 (2008).
17. Marotte H, Maslinski W, Miossec P: Circulating turnout necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res. Ther. 7(1), R149-R155 (2005).
18. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D: Polymorphism at position -308 of the tumor necrosis factor a gene influences outcome of Infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 48(7), 1849-1852 (2003).
19. Cuchacovich M, Ferreira L, Aliste M, et al.: Tumour necrosis factor-α (TNF-α) levels and influence of -308 TNF-α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 33(4), 228-232 (2004).
20. Cimaz R, Cazalis MA, Raynaud C et al.: IL-1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann. Rheum. Dis. 66(7), 900-904 (2007).
21. Ranganathan P: Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 6(5), 481-490 (2005).
22. Padyukov L, Lampa J, Heimburger M et al.: Genetic markers for the efficacy of tumor necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis. 62(6), 526-529 (2003).
23. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC: The influence of a polymorphism at position -857 of the tumour necrosis factor a gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxf.) 44 (4), 547-552 (2005).
24. Ranganathan P, McLeod HL: Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 54(5), 1366-1377 (2006).
25. US FDA: Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biologic products in pediatrics patients. Fed. Regist. 63(231), 66631-66672 (1998).
26. Regulation (EC) No 1901/2006 of the European Parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending regulation (EEC) No 726/2004. Official J. EUL378, 1-19 (2006).
27. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp. Med. 201(9), 1479-1486 (2005).
28. Lequerré T, Quartier P, Rosellini D et al.: Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67(3), 302-308 (2008).
29. Woo P: Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. Ann. Rheum. Dis. 67(3), 281-282 (2008).
30. Allantaz F, Chaussabel D, Stichweh D et al.: Blood leukocyte microarrays to diagnose systemic onset juventle idiopathic arthritis and follow the response to IL-1 blockade. J. Exp. Med. 204(9), 2131-2144 (2007).
31. Dinarello CA: Mutations in cryopyrin: bypassing roadblocks in the caspase 1 inflammasome for interleukin-1β secretion and disease activity. Arthritis Rheum. 56(9), 2817-2822 (2007).
32. Shaw NJ, Boivin CM, Crabtree NJ: Intravenous pamidronate in juvenile osteoporosis. Arch. Dis. Child. 83(2), 143-145 (2000).
33. Shoemaker LR: Expanding role of bisphosphonate therapy in children. J. Pediatr. 134(3), 264-267 (1999).
34. Srivastava T, Alon US: Bisphosphonates: from grandparents to grandchildren. Clin. Pediatr. 38(12), 687-702 (1999).
35. Noguera A, Ros JB, Pavia C et al.: Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J. Pediatr. Endocrinol. 16(4), 529-536 (2003).
36. Bianchi ML, Cimaz R, Bardare M et al.: Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children. Arthritis Rheum. 43(9), 1960-1966 (2000).
37. Cimaz R, Gattorno M, Sormani MP et al.: Changes in markers of bone turnover and inflammatory parameters during alendronate therapy in pediatric patients with rheumatic diseases. J. Rheumatol. 29(8), 1786-1792 (2002).
38. Simon D, Prieur AM, Quartler P, Charles Ruiz J, Czernichow P: Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin. Endocrinol. Metab. 92(7), 2567-2573 (2007).
39. Bechtold S, Ripperger P, Dalla Pozza R et al.: Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J. Clin. Endocrinol Metab. 92(8), 3013-3018 (2007).
40. Furuyama H, Odagawa Y, Katoh C et al.: Assessment of coronary function in children with history of Kawasaki disease using (15)O-water positron tomography. Circulation 105(24), 2878-2884 (2002).
41. Mavrogeni S, Papadopoulos G, Douskou M et al.: Magnetic resonance angiography is equivalent to x-ray coronary angiography for the evaluation of coronary arteries in Kawasaki disease. J. Am. Coll. Cardiol. 43(4), 649-652 (2004).
42. Hashino K, Ishii M, Iemura M, Akagi T, Kato H: Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 43(3), 211-217 (2001).
43. Jibiki T, Terai M, Kurosaki T et al.: Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur. J. Pediatr. 163(4-5), 229-233 (2004).
44. Lang BA, Yeung, SM, Oen KG et al.: Corticosteroid treatment of refractory Kawasaki disease. J. Rheumatol. 33(4), 803-809 (2006).
45. Newburger JW: Treatment of Kawasaki disease: corticosteroids revisited. J. Pediatr. 135(4), 411-413 (1999).
46. Takeshita S, Kawamura Y, Nakatan K: Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease. Clin. Pediatr. 44(5), 423-426 (2005).
47. Wooditch AC, Aronoff SC: Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-anallysis of 862 children. Pediatrics 116(4), 989-995 (2005).
48. Burns JC, Mason WH, Hauger SB et al.: Infliximab treatment for refractory Kawasaki syndrome. J. Pediatr 146(5), 662-667 (2005).
49. Stenbøg EV, Windelborg B, Hørlyck A, Herlin T: The effect of TNF α blockade in complicated, refractory Kawasaki disease. Scand. J. Rheumatol. 35 (4), 318-321 (2006).
50. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS: Infliximab as a novel therapy for refractory Kawasaki disease. J. Rheumatol. 31(4), 808-810 (2004).
51. Cheung YF, Yung TC, Tam SC et al.: Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis. J. Am. Coll. Cardiol. 43(1), 120-124 (2004).
52. Dhillon R, Clarkson P, Donald KE et al.: Endothelial dysfunction late after Kawasaki disease. Circulation 94(9), 2103-2106 (1996).
53. Furuyama H, Odagawa Y, Katoh C et al.: Altered myocardial flow reserve and endothelial function late after Kawasaki disease. J. Pediatr. 42 (2), 149-154 (2003).
54. Kato H, Inoue O, Kawasaki T et al.: Adult coronary artery disease probably due to childhood Kawasaki disease. Lancet 340(8828), 1127-1129 (1992).
55. Kato H, Sugimura T, Akag T: Long-term consequences of Kawasaki disease. A 10-to 21-year follow-up of 594 patients. Circulation94(6), 1379-1385 (1996).
56. Nakamura Y, Yanagawa, H, Harada K, Kato H, Kawasaki T: Mortality among persons with a history of Kawasaki disease in Japan: existence of cardiac sequelae elevated the mortality. J. Epidemiol. 10(6), 372-375 (2000).
57. Silva AA, Maeno Y, Hashmi A et al.: Cardiovascular risk factors after Kawasaki disease: a case-control study. J. Pediatr. 138(3), 400-405 (2001).